2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)
Galanis E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro A, Jaeckle KA, Kumar S, Kaufmann TJ, Geyer S, Kumthekar PU, Campian J, Giannini C, Buckner JC, Wen PY. Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-Oncology Advances 2022, 4: vdac041. PMID: 35664553, PMCID: PMC9154335, DOI: 10.1093/noajnl/vdac041.Peer-Reviewed Original ResearchProgression-free survivalRandomized phase II trialPhase II trialBevacizumab monotherapyRecurrent glioblastomaII trialTreatment armsMedian progression-free survivalLimited effective treatment optionsPhase IQuestionable survival benefitEarly clinical dataEffective treatment optionPhase IIQuality of lifeCombination armPrimary endpointAdverse eventsSurvival benefitLife scoresPoor prognosisTreatment optionsMechanisms of resistanceBevacizumabClinical data
2007
Lessons learned in the development of targeted therapy for malignant gliomas
Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Molecular Cancer Therapeutics 2007, 6: 1909-1919. PMID: 17620423, DOI: 10.1158/1535-7163.mct-07-0047.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor receptorEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsPreliminary efficacy resultsPrognosis of patientsTranslational researchEndothelial growth factor receptorEffective treatment optionTyrosine kinase inhibitorsGrowth factor receptorRecurrent diseaseRapamycin inhibitorsPreclinical dataStandard treatmentTreatment optionsEfficacy resultsMalignant gliomasSuch tumorsNovel agentsAnaplastic astrocytomaMost trialsTrial designProtein kinase C betaPathway inhibitor